Bio-Path Holdings, Inc.

Quick facts

Phase 2 pipeline

• BP1001 plus decitabine · Oncology
  Decitabine is a hypomethylating agent that targets DNA methyltransferase 1 (DNMT1)

Phase 1 pipeline

• BP1001
• BP1001 in combination with LDAC
• L-Bcl-2 antisense oligonucleotide

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Bio-Path Holdings, Inc. portfolio CI brief
• Bio-Path Holdings, Inc. pipeline updates RSS